Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA₁c < 7% with no hypoglycaemia and no weight gain over 2 years

Int J Clin Pract. 2013 Apr;67(4):317-21. doi: 10.1111/ijcp.12101.

Abstract

Linagliptin treatment for 104 weeks was recently reported to achieve non-inferior glucose-lowering effects compared with glimepiride in patients with type 2 diabetes inadequately controlled with metformin. Additional analyses from this randomised, active-controlled, double-blind trial have been performed in individuals completing the study on study drug without requiring rescue therapy. In this population, significantly more patients receiving linagliptin achieved HbA1c < 7% without hypoglycaemia and without body weight gain after 2 years compared with those receiving glimepiride (54% and 23%, respectively; odds ratio of 3.9, 95% confidence interval 2.6-5.7, p < 0.0001).

Trial registration: ClinicalTrials.gov NCT00622284.

Publication types

  • Clinical Trial, Phase III
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Glycated Hemoglobin / metabolism*
  • Humans
  • Hypoglycemia / prevention & control
  • Hypoglycemic Agents / administration & dosage*
  • Linagliptin
  • Male
  • Middle Aged
  • Purines / administration & dosage*
  • Quinazolines / administration & dosage*
  • Sulfonylurea Compounds / administration & dosage*
  • Treatment Outcome
  • Weight Gain / drug effects

Substances

  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Purines
  • Quinazolines
  • Sulfonylurea Compounds
  • Linagliptin
  • glimepiride

Associated data

  • ClinicalTrials.gov/NCT00622284